I was surprised the FDA gave, uh, this, the company such as Broad label for bronchiosis. I mean, generally speaking, labels end up looking like phase three trials, um, in terms of inclusion and exclusion criteria. Um, the phase three trial was very, you know, very clear, as was the phase two, you know, the particular patients that went into the trial, there were people at high risk for future exacerbations. Um, chiefly those with 2 or more in the last 12 months, uh, that, that puts them in that high risk group that we know is going to exacerbate more. So, I, I expected fully that label to read like that. Now, it doesn't. It was much more broad, and it just says it's indicated for bronchitis. Um, so, you know, presumably you can give it to people that don't fit that criteria, and I think some of us are. Um, but, you know, there are things that limit its use. I mean, a lot of these patients are on a lot of other medicines. Um, this medicine's also expensive. Some people have better coverage than others. Um, so there may be a copay involved, and that, that might not be OK for some patients. Um, you know, so, you know, it's not, it's not for everyone. I mean, not, not everyone should go on, on this medicine as bronchiectasis. It's really the people that you think are going to benefit. So, I mean, if I have patients, and I do, if they don't really exacerbate more than once a year or, or sometimes it's zero per year, They don't have a lot of daily symptoms, and there's really no point in giving them this. I wouldn't expect them to, to benefit. Um, but again, it's the people primarily that meet that phase 3 criteria. I mean, I do have some patients that, sure, maybe they only flare once a year, but they have a lot of symptoms. Um. And, you know, the data from the trial suggests that, you know, those patients may have a reduction in their symptoms. So I think for some people, even those that aren't flaring that frequently, they have a lot of symptoms. They may also be a good candidate for this.
Presenter
